{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282681254607232.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.11250/chemotherapy1953.40.1499"}},{"identifier":{"@type":"NAID","@value":"130004197712"}}],"dc:title":[{"@language":"en","@value":"Comparative clinical study of cefditoren pivoxil and cefteram pivoxil for chronic respiratory tract infections by a double-blind method."},{"@value":"慢性気道感染性に対するｃｅｆｄｉｔｏｒｅｎ　ｐｉｖｏｘｉｌとｃｅｆｔｅｒａｍ　ｐｉｖｏｘｉｌの薬効比較試験成績"}],"dc:language":"ja","description":[{"type":"abstract","notation":[{"@language":"en","@value":"A double-blind comparative study was carried out to determine the effficacy, safety and usefulness of cefditoren pivoxil (CDTR-PI), a new oral cephem, in the treatment of chronic respiratory tract infections, using cefteram pivoxil (CFTM-PI) as the reference drug. In principle, patients were treated by oral administration of either CDTR-PI or CFTM-PI at 200mg three times daily for 14 days. The following results were obtained.<BR>(1) The Clinical effficacy rate as judged by the committee was 85.9% (73/85) in the CDTR-PI group and 85.9% (67/78) in the CFTM-PI group, with no significant difference between the two treatment groups.<BR>(2) As to the bacteriological effifficacy as judged by the committee, the eradication rate was 84.2% (32/38) in the CDTR-PI group and 77.8% (28/36) in the CFTM-PI group. No significant difference was seen between the two treatment groups.<BR>(3) The incidence of side effects was 9.3% (9/97) in the CDTR-PI group and 6.3% (6/95) in the CFTM-PI group, and the incidence of abnormal laboratory findings 12.4% (11/89) and 11.5% (10/87), respectively, as judged by the committee. There was no significant differeance between the two groups.<BR>(4) The usefulness rate as judged by the committee was 80.2% (69/86) in the CDTR-PI group and 82.5% (66/80) in the CFTM-PI group, the difference not being significant.<BR>From these results it is concluded that CDTR-PI is an oral antibiotic with high usefulness in the treatment of chronic respiratory tract infections."},{"@value":"新しい経口用セフェム剤cefditoren pivoxil (CDTR-PI) の慢性気道感染症に対する有効性, 安全性および有用性を検討する目的で, cefteram pivoxil (CFTM-PI) を対照薬として二重盲検法により比較検討した。投与量はCDTR-PI, CFTM-PIともに1回200mgで, いずれも1日3回, 原則として14日間経口投与し, 以下の結果を得た。<BR>(1) 委員会判定による臨床効果はCDTR-PI群85.9% (73/85), CFTM-PI群85.9% (67/78) の有効率で両薬剤群間に有意差は認められなかった。<BR>(2) 委員会判定による細菌学的効果はCDTR-PI群84.2% (32/38), CFTM-PI群77.8% (28/36) の菌消失率で両薬剤群間に有意な差は認められなかった。<BR>(3) 委員会判定による副作用はCDTR-PI群9.3% (9/97), CFTM-PI群6.3% (6/95), 臨床検査値異常は, それぞれ12.4% (11/89), 11.5% (10/87) の発現率で, いずれも両薬剤群間に有意差は認められなかった。<BR>(4) 委員会判定による有用性は, 有用率 (有用以上) CDTR-PI群80.2% (69/86), CFTM-PI群82.5% (66/80) で両薬剤群間に有意差は認められなかった。<BR>以上より, CDTR-PIは慢性気道感染症に対し有用性の高い薬剤であると考えられた。"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410282681254607232","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000256178901"}],"foaf:name":[{"@language":"en","@value":"Shiba Kohya"},{"@language":"ja","@value":"柴 孝也他"}],"jpcoar:affiliationName":[{"@language":"en","@value":"The Second Department of Internal Medicine, The Jikei University School of Medicine"},{"@language":"ja","@value":"東京慈恵会医科大学第二内科"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00093165"},{"@type":"EISSN","@value":"18845894"}],"prism:publicationName":[{"@language":"en","@value":"CHEMOTHERAPY"},{"@language":"ja","@value":"ＣＨＥＭＯＴＨＥＲＡＰＹ"},{"@language":"en","@value":"Chemother."},{"@language":"ja","@value":"ＣＨＥＭＯＴＨＥＲＡＰＹ"}],"dc:publisher":[{"@language":"en","@value":"Japanese Society of Chemotherapy"},{"@language":"ja","@value":"公益社団法人 日本化学療法学会"}],"prism:publicationDate":"1992","prism:volume":"40","prism:number":"12","prism:startingPage":"1499","prism:endingPage":"1528"},"availableAt":"1992","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Double%20blind%20study","dc:title":"Double blind study"},{"@id":"https://cir.nii.ac.jp/all?q=cefteram%20pivoxil","dc:title":"cefteram pivoxil"},{"@id":"https://cir.nii.ac.jp/all?q=CDTR-PI","dc:title":"CDTR-PI"},{"@id":"https://cir.nii.ac.jp/all?q=%E6%85%A2%E6%80%A7%E6%B0%97%E9%81%93%E6%84%9F%E6%9F%93%E7%97%87","dc:title":"慢性気道感染症"},{"@id":"https://cir.nii.ac.jp/all?q=CDTR","dc:title":"CDTR"}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:0007921756"},{"@type":"CIA","@value":"130004197712"}]}